Skip to content

$894 Million Settlement Against Pfizer for Bextra and Celebrex

What Happened? The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the […]

October 17, 2008

What Happened?

The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the United States and represented approximately 400 claimants. In 2005, Pfizer withdrew Bextra from the market, while Celebrex remained, but with a required Black Box safety warning regarding the risk of heart attacks and strokes.

How Was the Settlement Structured?

Seeger Weiss LLP founding partner Christopher A. Seeger, a member of the Plaintiffs’ Steering Committee in the Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, helped to shape the $894 million settlement which was announced by Pfizer on October 17, 2008.

In total, there were several thousand lawsuits filed against Pfizer because of Bextra and Celebrex related injuries and deaths. The settlement figure announced was split up to deal with the various claims that were brought against Pfizer:

  • $745 million went toward personal-injury lawsuits;
  • $60 million went to states regarding the Bextra marketing claims; and
  • $89 million was allocated to resolve the consumer-fraud cases.

What is the Current Status of Bextra and Celebrex Lawsuits?

A Securities Class Action Against Pfizer Settled for $486 Million

In 2016, a related securities class action lawsuit filed by investors in 2004, was settled for $486 million. The investors claimed that Pfizer concealed information regarding studies of Bextra and Celebrex, that demonstrated the drugs might increase the risk of heart attacks and strokes. Once the studies were released to the public, and Bextra was pulled from the market, Pfizer’s share price dropped, and investors suffered losses.

Related News

December 1, 2022
Seeger Weiss now accepting applicants for 2023 Diversity Fellowship

Seeger Weiss LLP announced today that the application period for the firm’s 2023 Diversity Fellowship is now open. Seeger Weiss is committed to providing an inclusive, equitable workplace where team members from all backgrounds can thrive and grow. We believe that diversity makes workplaces, institutions, and our world stronger, smarter, more resilient, and more just. […]

Read More
November 11, 2022
Chris Seeger appointed co-lead counsel in In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation

Seeger Weiss is proud to announce founder Chris Seeger has been appointed to serve as co-lead counsel in the In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation by the honorable Judge Yvonne Gonzalez Rogers. Seeger was one of three lawyers selected to lead the multidistrict litigation pending in the Northern District of California, […]

Read More
November 4, 2022
Seeger Weiss founding partner Chris Seeger helps negotiate $10 billion agreements with Walgreens and CVS in National Prescription Opiate Litigation

Seeger Weiss founding partner Chris Seeger along with partner Jennifer Scullion helped lead the National Prescription Opiate Litigation team in negotiations with Walgreens and CVS that culminated in over $10 billion in settlement agreements to help communities across the country ravaged by the opioid epidemic. In addition to Seeger and Scullion, negotiations were led by […]

Read More